All In Biotech

Drug Trial Radar · NCT03972722

Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer

An Open, Multi-center, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Fully Human Anti-PD-1 Monoclonal Antibody (GLS-010 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

Last checked: Nov 19, 2026Latest source record: Jun 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

89

Planned (sponsor's estimate)

Start

May 15, 2019

Primary completion

May 15, 2022

Study completion May 15, 2023

Sponsor

Sponsor type
Industry
First posted
Jun 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with recurrent or metastatic cervical cancer,and will be treated with GLS-010.

Conditions

  • Cervical Cancer

Interventions

  • GLS-010Drug

    Patients will be given 240mg GLS-010 every treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rateTime frame: within 27 Months after patient enrolled

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.